# Innovatus Capital Partners

> Innovatus Capital Partners is a VC fund backing Health Care and Biotechnology. See 24 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 24
- Last investment: Sep 2025
- Lead investor: 63%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/innovatus-capital-partners/
- Website: http://www.innovatuscp.com/

Innovatus Capital Partners is a VC fund in New York focused on Health Care and Biotechnology. Innovatus Capital Partners, they focus on both real and financial assets. Their firm's investment in strategies that identifies distressed, disruptive, and growth opportunities.

## Contacts

5 contacts available for Innovatus Capital Partners. Shizune tracks 3 team members at Innovatus Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/innovatus-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 11 | 46% |
| Biotechnology | 10 | 42% |
| Medical | 6 | 25% |
| Medical Device | 5 | 21% |
| Health Diagnostics | 5 | 21% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Debt | 7 | 29% |
| Series D | 3 | 13% |
| Series C | 2 | 8% |
| Post-IPO Equity | 2 | 8% |
| Seed | 1 | 4% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 15 | 63% |
| Germany | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Claes Ekstrom | Investment Team & Managing Director - Head of Life Sciences | 10 | https://shizune.co/investors/profile/claes-ekstrom |
| Andrew Dym | Founding Partner | 0 | https://shizune.co/investors/profile/andrew-dym-6f13 |
| David Schiff | Founding Partner | 0 | https://shizune.co/investors/profile/david-schiff-6d01 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Celcuity | Celcuity is a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving apatient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. | $500M | Post-IPO Debt | Sep 09, 2025 |  |
| Codexis | Codexis, Inc. is an industrial biotechnology company that specializes in engineers enzymes for pharmaceutical and chemical production through biocatalysis. Codexis’ technologies enable scale-up and implementation of biocatalytic solutions to optimize process development, from research to manufacturing. There are currently over 50 pharmaceuticalfirms using Codexis’ technology, products and services in their manufacturing process development.Codexis creates its products by applying its CodeEvolver® directed evolution technology platform, which introduces genetic mutations into microorganisms.Codexis, Inc. began operations as an independent company in 2002, and became a publicly traded company in 2009. They are located in Redwood City, CA USA |  | Post-IPO Debt | Aug 13, 2025 |  |
| Imperative Care | Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $150M | Series E | Jul 25, 2024 |  |
| Celcuity | Celcuity is a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving apatient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. | $62M | Post-IPO Debt | May 30, 2024 |  |
| Codexis | Codexis, Inc. is an industrial biotechnology company that specializes in engineers enzymes for pharmaceutical and chemical production through biocatalysis. Codexis’ technologies enable scale-up and implementation of biocatalytic solutions to optimize process development, from research to manufacturing. There are currently over 50 pharmaceuticalfirms using Codexis’ technology, products and services in their manufacturing process development.Codexis creates its products by applying its CodeEvolver® directed evolution technology platform, which introduces genetic mutations into microorganisms.Codexis, Inc. began operations as an independent company in 2002, and became a publicly traded company in 2009. They are located in Redwood City, CA USA | $30M | Post-IPO Debt | Feb 13, 2024 |  |
| JenaValve Technology | JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $100M | Series C | Aug 31, 2022 |  |
| MDxHealth | MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. | $35M | Post-IPO Debt | Aug 02, 2022 |  |
| Syapse | To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions thatmatter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond. | $35M | Venture - Series Unknown | Jul 27, 2022 |  |
| Eiger BioPharmaceuticals | Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Itsstrategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients. | $5M | Post-IPO Equity | Jun 07, 2022 |  |
| Eiger BioPharmaceuticals | Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Itsstrategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients. | $75M | Post-IPO Debt | Jun 07, 2022 |  |

10 of 24 investments shown.

## Co-investors
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 3 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 3 deals together
- [Northpond Ventures](https://shizune.co/investors/profile/northpond-ventures) — VC Fund, 3 deals together
- [Rock Springs Capital](https://shizune.co/investors/profile/rock-springs-capital) — VC Fund, 3 deals together
- [AMED Ventures](https://shizune.co/investors/profile/amed-ventures) — VC Fund, 2 deals together
- [Ascension Ventures](https://shizune.co/investors/profile/ascension-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [BNP Paribas](https://shizune.co/investors/profile/bnp-paribas) — VC Fund
- [Intesa Sanpaolo](https://shizune.co/investors/profile/intesa-sanpaolo) — VC Fund
- [UniCredit](https://shizune.co/investors/profile/unicredit) — VC Fund

## FAQ

### What does Innovatus Capital Partners invest in?

Innovatus Capital Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Post-IPO Debt and Series D stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Innovatus Capital Partners?

Public channels for Innovatus Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Innovatus Capital Partners?

The team at Innovatus Capital Partners includes Claes Ekstrom (Investment Team & Managing Director - Head of Life Sciences), Andrew Dym (Founding Partner) and David Schiff (Founding Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co